ATE509032T1 - Chimerizierte gm-csf antikörper - Google Patents

Chimerizierte gm-csf antikörper

Info

Publication number
ATE509032T1
ATE509032T1 AT03713430T AT03713430T ATE509032T1 AT E509032 T1 ATE509032 T1 AT E509032T1 AT 03713430 T AT03713430 T AT 03713430T AT 03713430 T AT03713430 T AT 03713430T AT E509032 T1 ATE509032 T1 AT E509032T1
Authority
AT
Austria
Prior art keywords
antibodies
chimerized
disclosed
well
fusion proteins
Prior art date
Application number
AT03713430T
Other languages
English (en)
Inventor
Christoph Renner
Andrew Scott
Antony Burgess
Original Assignee
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst For Cancer Res Ltd filed Critical Ludwig Inst For Cancer Res Ltd
Application granted granted Critical
Publication of ATE509032T1 publication Critical patent/ATE509032T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
AT03713430T 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper ATE509032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35583802P 2002-02-13 2002-02-13
PCT/US2003/004185 WO2003068920A2 (en) 2002-02-13 2003-02-12 Humanized gm-csf antibodies

Publications (1)

Publication Number Publication Date
ATE509032T1 true ATE509032T1 (de) 2011-05-15

Family

ID=27734567

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
AT03713430T ATE509032T1 (de) 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon

Country Status (8)

Country Link
US (5) US7381801B2 (de)
EP (2) EP1530580B1 (de)
JP (1) JP2006500905A (de)
AT (2) ATE444308T1 (de)
AU (2) AU2003215188A1 (de)
DE (1) DE60329489D1 (de)
ES (1) ES2365606T3 (de)
WO (2) WO2003068920A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
CA2492057A1 (en) 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EP2497497B1 (de) 2004-07-02 2017-06-21 Wilex AG Verbesserte adjuvans therapie für g250 exprimierende tumore
PT1874819E (pt) * 2005-04-18 2015-09-17 Amgen Res Munich Gmbh Neutralizadores de anticorpos do fator humano de estimulação de colónias de macrófagos e granulócitos
KR101308087B1 (ko) * 2005-05-18 2013-10-16 모르포시스 아게 항-ｇｍ-ｃｓｆ 항체 및 이의 용도
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
PL1981909T3 (pl) 2006-02-08 2017-08-31 Morphotek, Inc. Antygenowe peptydy GM-CSF oraz przeciwciała wobec GM-CSF
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
BRPI0719109A2 (pt) 2006-11-21 2013-12-10 Kalobios Pharmaceuticals Inc Métodos para tratar doenças inflamatórias crônicas usando um antagonista de gm-csf
EP2126127B1 (de) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
EP2160407A4 (de) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd Neutralisierende antikörper
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CA2705539A1 (en) * 2007-11-13 2009-05-22 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
CA2711763A1 (en) * 2008-01-15 2009-07-23 Kalobios Pharmaceuticals, Inc. Methods of treating bone-loss disorders using a gm-csf antagonist
CA2720614A1 (en) * 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
KR101852915B1 (ko) * 2008-04-28 2018-04-27 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
MX2011000041A (es) * 2008-07-02 2011-05-23 Emergent Product Dev Seattle Proteinas antagonistas del factor-alfa de necrosis tumoral (tnf-alfa), de union a multiples objetivos.
KR101706789B1 (ko) * 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
US8518406B2 (en) * 2008-08-20 2013-08-27 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE)
CN108014335A (zh) 2008-12-22 2018-05-11 墨尔本大学 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途
CN106397591A (zh) 2008-12-22 2017-02-15 墨尔本大学 骨关节炎治疗
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
PL3470421T3 (pl) 2010-07-29 2023-10-23 Buzzard Pharmaceuticals AB Chimeryczne antagonisty receptora il-1 typu i
KR20140061379A (ko) 2011-07-06 2014-05-21 모르포시스 아게 항­ｃｄ20 및 항­ｇｍ­ｃｓｆ 항체의 치료 조합물 및 이의 용도
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2968468B1 (de) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimäre zytokine formulierungen zur okularen verabreichung
ES2860480T3 (es) 2013-08-30 2021-10-05 Takeda Gmbh Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
CA2944775A1 (en) * 2014-04-04 2015-10-08 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
US9714953B2 (en) 2014-04-04 2017-07-25 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
CN112166122A (zh) * 2018-12-13 2021-01-01 丁邦 抗体-肿瘤坏死因子α融合蛋白及其制法和应用
US20210284744A1 (en) * 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
EP0366707A1 (de) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoklonale antikörper gegen nierenzellen-karzinom
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
FR2723462B1 (fr) 1994-08-02 1996-09-06 Thomson Lcd Procede d'adressage optimise d'ecran a cristaux liquides et dispositif pour sa mise en oeuvre
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体

Also Published As

Publication number Publication date
ES2365606T3 (es) 2011-10-07
DE60329489D1 (de) 2009-11-12
EP1530580B1 (de) 2011-05-11
AU2003217386A1 (en) 2003-09-04
US20040053365A1 (en) 2004-03-18
AU2003217386B2 (en) 2008-06-26
EP1507859A4 (de) 2007-05-30
EP1507859A2 (de) 2005-02-23
JP2006500905A (ja) 2006-01-12
EP1530580A4 (de) 2006-02-01
AU2003215188A8 (en) 2003-09-04
US7714113B2 (en) 2010-05-11
WO2003068924A2 (en) 2003-08-21
EP1507859B1 (de) 2009-09-30
WO2003068920A9 (en) 2004-06-03
US20090259027A1 (en) 2009-10-15
EP1530580A2 (de) 2005-05-18
WO2003068924A3 (en) 2004-12-29
US7381801B2 (en) 2008-06-03
US7897743B2 (en) 2011-03-01
WO2003068920A8 (en) 2004-07-29
WO2003068920A3 (en) 2004-07-01
WO2003068920A2 (en) 2003-08-21
US20060045876A1 (en) 2006-03-02
AU2003215188A1 (en) 2003-09-04
ATE444308T1 (de) 2009-10-15
US20120029172A1 (en) 2012-02-02
US20100167395A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
ATE509032T1 (de) Chimerizierte gm-csf antikörper
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2005012493A3 (en) Anti-cd19 antibodies
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
CY1119106T1 (el) Αντισωματα εναντι masp-2
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
DK1641483T3 (da) Fusionsproteiner
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
ATE393169T1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
TW200510459A (en) RG1 antibodies and uses thereof
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2004093808A3 (en) Novel tumor-associated antigens
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2003102017A3 (en) Anti-relp fusion antibodies, compositions, methods and uses
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
DE60130804D1 (de) Antagonistischer antikörper gegen pro842
WO2005047456A3 (en) Anti-idiotype antibodies of the human monoclonal antibody sc-1, and their production and use
TW200500465A (en) Novel humanized anti-vap-1 monoclonal antibody

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties